Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) EPS (Basic) (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed EPS (Basic) for 14 consecutive years, with -$0.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 92.62% year-over-year to -$0.0, compared with a TTM value of -$0.0 through Nov 2025, up 92.62%, and an annual FY2025 reading of -$0.0, up 82.68% over the prior year.
  • EPS (Basic) was -$0.0 for Q4 2025 at CNBX Pharmaceuticals, up from -$0.0 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.19 in Q3 2021 and bottomed at -$2.26 in Q1 2022.
  • Average EPS (Basic) over 5 years is -$0.05, with a median of -$0.0 recorded in 2024.
  • The sharpest move saw EPS (Basic) surged 31385.71% in 2021, then plummeted 15166.67% in 2022.
  • Year by year, EPS (Basic) stood at -$0.01 in 2021, then crashed by 3200.0% to -$0.33 in 2022, then soared by 98.12% to -$0.01 in 2023, then soared by 80.88% to -$0.0 in 2024, then soared by 92.62% to -$0.0 in 2025.
  • Business Quant data shows EPS (Basic) for CNBX at -$0.0 in Q4 2025, -$0.0 in Q3 2025, and -$0.0 in Q2 2025.